Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30989806 | 0.89 | GRM5 (0.45) | TACR1HPGD | |
| SCHEMBL30989812 | 0.88 | MEP1B (0.44) | LMNAHPGD | |
| SCHEMBL30989861 | 0.88 | RIPK1 (0.49) | PTGER4PDK1HPGD | |
| SCHEMBL30989923 | 0.87 | ALDH1A1 (0.47) | PTGER4HPGD | |
| SCHEMBL30989857 | 0.87 | HSP90AA1 (0.52) | TACR1PDK1 | |
| SCHEMBL30989922 | 0.85 | POLB (0.49) | LMNAHPGD | |
| SCHEMBL30989865 | 0.84 | PTGER4 (0.41) | PTGER4PDK1 | |
| SCHEMBL30989818 | 0.83 | ALDH1A1 (0.45) | TACR1HPGD | |
| SCHEMBL30989808 | 0.81 | HTT (0.39) | TACR1PTGER4HPGD | |
| SCHEMBL30989793 | 0.79 | HTT (0.38) | TACR1PTGER4GPBAR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |